208 related articles for article (PubMed ID: 32360010)
21. Renin-angiotensin-aldosterone system inhibitors and COVID-19.
Quinn KL; Fralick M; Zipursky JS; Stall NM
CMAJ; 2020 May; 192(20):E553-E554. PubMed ID: 32332039
[No Abstract] [Full Text] [Related]
22. [Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].
Mareev YV; Mareev VY
Kardiologiia; 2020 Apr; 60(4):4-9. PubMed ID: 32394850
[TBL] [Abstract][Full Text] [Related]
23. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
Ingraham NE; Barakat AG; Reilkoff R; Bezdicek T; Schacker T; Chipman JG; Tignanelli CJ; Puskarich MA
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32341103
[TBL] [Abstract][Full Text] [Related]
24. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA
Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399
[No Abstract] [Full Text] [Related]
26. [Renin-angiotensin system blockers and COVID-19 infection].
Ruilope LM; Garcia Donaire JA; de la Sierra A
Hipertens Riesgo Vasc; 2020; 37(3):99-100. PubMed ID: 32448641
[No Abstract] [Full Text] [Related]
27. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
28. COVID-19: The heart of the issue.
Woodward B; Kermali M
J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
[No Abstract] [Full Text] [Related]
29. Angiotensin receptor blockers for the treatment of COVID-19 and its comorbidities.
Saavedra JM
Pharmacol Res; 2020 Sep; 159():104958. PubMed ID: 32473311
[No Abstract] [Full Text] [Related]
30. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.
Tomasoni D; Italia L; Adamo M; Inciardi RM; Lombardi CM; Solomon SD; Metra M
Eur J Heart Fail; 2020 Jun; 22(6):957-966. PubMed ID: 32412156
[TBL] [Abstract][Full Text] [Related]
31. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
32. Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
Turgeon RD; Zieroth S; Bewick D; Chow CM; Clarke B; Cowan S; Fordyce CB; Fournier A; Gin K; Gupta A; Hardiman S; Jackson S; Lau B; Leong-Poi H; Mansour S; Marelli A; Quraishi AR; Roifman I; Ruel M; Sapp J; Singh G; Small G; Virani S; Wood DA; Krahn A
Can J Cardiol; 2020 Aug; 36(8):1180-1182. PubMed ID: 32502522
[No Abstract] [Full Text] [Related]
33. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
Baral R; White M; Vassiliou VS
Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
[TBL] [Abstract][Full Text] [Related]
34. [Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19].
;
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jul; 48(7):565-566. PubMed ID: 32842268
[TBL] [Abstract][Full Text] [Related]
35. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
Rossi GP; Sanga V; Barton M
Elife; 2020 Apr; 9():. PubMed ID: 32250244
[TBL] [Abstract][Full Text] [Related]
36. Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19.
Tan ND; Qiu Y; Xing XB; Ghosh S; Chen MH; Mao R
Gastroenterology; 2020 Sep; 159(3):1170-1172.e1. PubMed ID: 32422208
[No Abstract] [Full Text] [Related]
37. Kidney injury associated with COVID-19.
Blum D; Meraz-Munoz A; Harel Z
CMAJ; 2020 Sep; 192(37):E1065. PubMed ID: 32928802
[No Abstract] [Full Text] [Related]
38. Cardiovascular disease and the impact of COVID-19.
Yoganathan A; Sajjad MS; Harky A
J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
[No Abstract] [Full Text] [Related]
39. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
[No Abstract] [Full Text] [Related]
40. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Danser AHJ; Epstein M; Batlle D
Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
